recombination signal binding protein for immunoglobulin kappa J regionGenealiases: AOS3 · CBF-1 · CBF1 · IGKJRB · IGKJRB1 · KBF2
Q-omics provides the consensus-scored RBPJ profile across patient tissues and cancer cell-line models. RBPJ expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RBPJ is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RBPJ RNA expression shows 19,815 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where RBPJ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBPJ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBPJ survival associations across molecular data types. RBPJ RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBPJ RNA expression–survival associations across cancer types. High RBPJ expression shows unfavorable associations in MESO, UVM, LIHC and KICH, but favorable associations in UCEC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RBPJ RNA expression.
This table summarizes RBPJ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBPJ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBPJ shows lower tumor expression in BLCA and THCA and higher tumor expression in HNSC, KIRC, LIHC and CHOL. The HNSC box plot shows higher RBPJ RNA expression in tumor versus normal tissue (log2 FC = +1.093, t-test p < 0.001).
This table shows molecular features associated with RBPJ in patient tissues and cancer cell lines. In patient samples, RBPJ shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBPJ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
